Related Experiment Video
Updated: Jun 25, 2026
09:01
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
Ulcerative colitis in AKR mice is attenuated by intraperitoneally administered anandamide
M A Engel1, C A Kellermann, T Rau
1First Department of Medicine, University of Erlangen-Nuremberg, Germany. Matthias.Engel@uk-erlangen.de
Summary
The endogenous cannabinoid anandamide (N-arachidonylethanolamine) effectively reduced experimental colitis in mice. This suggests cannabinoid compounds may offer therapeutic potential for inflammatory bowel disease (IBD) treatment.
Area of Science:
- Immunology
- Pharmacology
- Gastroenterology
Background:
- Endocannabinoids and synthetic cannabinoids exhibit anti-inflammatory and anti-nociceptive effects.
- Anandamide (N-arachidonylethanolamine) is an endogenous cannabinoid with potential therapeutic applications.
Purpose of the Study:
- To investigate the effects of anandamide on experimental colitis induced by TNBS (2,4,6-trinitrobenzene sulfonic acid).
- To evaluate the therapeutic potential of anandamide in treating inflammatory bowel disease (IBD).
Main Methods:
- Experimental colitis was induced in AKR mice using TNBS.
- Anandamide was administered intraperitoneally.
- Clinical and macroscopic changes were assessed using scoring systems.
- Pro-inflammatory cytokine mRNA expression was measured.
Main Results:
- Intraperitoneal administration of anandamide significantly attenuated experimental colitis.
- Anandamide reduced colitis severity based on macroscopic and histological scoring.
- Pro-inflammatory cytokine mRNA expression was significantly decreased by anandamide treatment.
Conclusions:
- Systemically administered anandamide effectively reduces TNBS-induced colitis in mice.
- Systemically active cannabinoid compounds demonstrate therapeutic potential for managing IBD.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...